Applying both concepts and assays derived from prion diseases, we were able to successfully amplify misfolded tau seeds from AD brains using an engineered tau fragment 4RCF, and each of the six individual full-length wild-type tau isoforms as a substrate. The gene discussed is MAPT; the disease is Alzheimer disease.